AnaptysBio, Inc. (ANAB) News
Filter ANAB News Items
ANAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANAB News Highlights
- ANAB's 30 day story count now stands at 2.
- Over the past 20 days, the trend for ANAB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest ANAB News From Around the Web
Below are the latest news stories about ANAPTYSBIO INC that investors may wish to consider to help them evaluate ANAB as an investment opportunity.
AnaptysBio (NASDAQ:ANAB) shareholders have endured a 66% loss from investing in the stock five years agoOver the last month the AnaptysBio, Inc. ( NASDAQ:ANAB ) has been much stronger than before, rebounding by 50%. But... |
Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect?The consensus price target hints at a 69.4% upside potential for AnaptysBio, Inc. (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsAnaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolioIND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2024Reiterating year-end 2023 cash and investments of $400 to $410 million and cash runway through year-end 2026 SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative |
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD DrugDespite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States. |
MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis StudyThough data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint. |
Revenue Downgrade: Here's What Analysts Forecast For AnaptysBio, Inc. (NASDAQ:ANAB)One thing we could say about the analysts on AnaptysBio, Inc. ( NASDAQ:ANAB ) - they aren't optimistic, having just... |
Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a TurnaroundAnaptysBio, Inc. (ANAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
Anaptys Named a BioSpace 2024 Best Places to Work WinnerSAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for the second year in a row, it has been named a BioSpace 2024 Best Place to Work in the small employer category. “This award acknowledges the commitment we’ve made to ensuring Anaptys provides our employees with an exceptional experience throughout their careers,” said Beth Mueller, senior vice presi |
AnaptysBio, Inc. (NASDAQ:ANAB) Is Expected To Breakeven In The Near FutureWith the business potentially at an important milestone, we thought we'd take a closer look at AnaptysBio, Inc.'s... |
AnaptysBio Inc (ANAB) Reports Q3 2023 Financial Results and Business UpdatesCompany announces positive Phase 3 clinical trial results and anticipates year-end cash and investments of $400 to $410 million |